These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32933922)

  • 21. Role of Metrology in Axial Spondyloarthritis: Does It Provide Unique Information in Assessing Patients and Predicting Outcome? Results From the British Society for Rheumatology Biologic Register for Ankylosing Spondylitis.
    Biallas RL; Dean LE; Davidson L; Hollick R; Pathan E; Robertson L; Jones GT; Macfarlane GJ; Rotariu O
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):665-674. PubMed ID: 33140891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
    Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
    Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stable bone turnover markers corrected for age and gender during the first year of secukinumab treatment in radiographic axial spondyloarthritis.
    Siderius M; Arends S; Wink F; Kroese FGM; Spoorenberg A
    Clin Exp Rheumatol; 2023 Sep; 41(9):1942-1943. PubMed ID: 37223930
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment persistence of tumour necrosis factors and IL-17 inhibitors in axial spondyloarthritis: A multi-center comparative analysis.
    Delépine T; Philippe P; Cailliau E; Houvenagel E; Pascart T; Deprez X; Flipo RM; Letarouilly JG
    Joint Bone Spine; 2022 Nov; 89(6):105416. PubMed ID: 35636707
    [No Abstract]   [Full Text] [Related]  

  • 25. IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
    Torgutalp M; Poddubnyy D
    Expert Opin Biol Ther; 2019 Jul; 19(7):631-641. PubMed ID: 30957574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
    Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
    Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update".
    Braun J
    Ann Rheum Dis; 2023 Sep; 82(9):e205. PubMed ID: 36737105
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
    Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
    Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO.
    Llop M; Moreno M; Navarro-Compán V; Juanola X; de Miguel E; Almodóvar R; Quintana EC; Sanz JS; Beltrán E; Montesinos MDR; Calvet J; Berenguer-Llergo A; Gratacós J;
    Arthritis Res Ther; 2022 Jan; 24(1):30. PubMed ID: 35063018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis.
    Hiltunen J; Parmanne P; Sokka T; Lamberg T; Isomäki P; Kaipiainen-Seppänen O; Peltomaa R; Uutela T; Pirilä L; Taimen K; Kauppi MJ; Yli-Kerttula T; Tuompo R; Relas H; Kortelainen S; Paalanen K; Asikainen J; Ekman P; Santisteban A; Vidqvist KL; Tadesse K; Romu M; Borodina J; Elfving P; Valleala H; Leirisalo-Repo M; Rantalaiho V; Kautiainen H; Jokiranta TS; Eklund KK;
    Rheumatol Int; 2022 Jun; 42(6):1015-1025. PubMed ID: 34357455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis.
    Huang Y; Chen Y; Liu T; Lin S; Yin G; Xie Q
    PLoS One; 2020; 15(12):e0244788. PubMed ID: 33382842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort.
    Torgutalp M; Rios Rodriguez V; Proft F; Protopopov M; Verba M; Rademacher J; Haibel H; Sieper J; Rudwaleit M; Poddubnyy D
    Arthritis Rheumatol; 2022 Sep; 74(9):1515-1523. PubMed ID: 35437900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
    Apaydin H; Dogan I; Erten Ş
    Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-TNF response rates in radiographic and non-radiographic axial spondyloarthropathy.
    McCormick D; McKnight J; Pendleton A
    Ann Rheum Dis; 2015 Mar; 74(3):e21. PubMed ID: 25371443
    [No Abstract]   [Full Text] [Related]  

  • 35. Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto
    Kiltz U; Braun J
    Ann Rheum Dis; 2023 Dec; 82(12):e229. PubMed ID: 34725049
    [No Abstract]   [Full Text] [Related]  

  • 36. Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study.
    Sun Y; Wang J; Qiu Y; Lin S; Wang F; Tan W
    Chin Med J (Engl); 2022 Nov; 135(21):2623-2624. PubMed ID: 36583925
    [No Abstract]   [Full Text] [Related]  

  • 37. Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'.
    Zhao Y; Huang JX
    Ann Rheum Dis; 2023 Jul; 82(7):e168. PubMed ID: 34172501
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina
    Duret PM; Spielmann L; Messer L
    Ann Rheum Dis; 2021 May; 80(5):e80. PubMed ID: 32816687
    [No Abstract]   [Full Text] [Related]  

  • 39. Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study.
    Kömel Pimenta PR; Ribeiro da Silva MR; Ribeiro Dos Santos JB; Kakehasi AM; Assis Acurcio F; Alvares-Teodoro J
    J Comp Eff Res; 2021 Apr; 10(6):509-517. PubMed ID: 33728937
    [No Abstract]   [Full Text] [Related]  

  • 40. Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang.
    Wei JC; Kim TH; Kishimoto M; Ogusu N; Jeong H; Kobayashi S
    Ann Rheum Dis; 2023 Jul; 82(7):e169. PubMed ID: 34172504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.